• Explore /
  • Poster
  • / Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI).

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI).

Abstract Poster

Authors

null

Emmanuelle Samalin

Institut du Cancer de Montpellier and IRCM, Université de Montpellier, Montpellier, France;

Emmanuelle Samalin , Hélène Senellart , Ludovic Evesque , Olivier Bouché , Faiza Khemissa , Christelle De La Fouchardiere , Anthony Lopez , Slimane Dermeche , Damien Botsen , David Tougeron , Aziz Zaanan , Meher BEN Abdelghani , Emmanuel Guardiola , Olivier Dubreuil , Valérie Le Brun Ly , Audrey Hennequin , Nicolas De Sousa Carvalho , Florence Castan , Anthony Turpin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03722108

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 387)

DOI

10.1200/JCO.2023.41.4_suppl.387

Abstract #

387

Poster Bd #

G9

Abstract Disclosures

Similar Posters

First Author: Peter C. Thuss-Patience

First Author: Nicolas Huyghe

First Author: Sylvie Lorenzen

First Author: Ming-Huang Chen